Platelet glycoprotein receptors and primary hemostasis machinery

Platelet glycoprotein receptors and the primary hemostasis machinery comprise a complex network of surface proteins and signaling molecules essential for the initial response to vascular injury (Oncohemakey, NIH). Primary hemostasis involves the formation of a platelet plug through three main stages: adhesion, activation, and aggregation (Khan Academy). Adhesion is mediated by the GPIb-IX-V complex binding to von Willebrand factor (vWF) and GPVI or integrin alpha2 beta1 binding to exposed collagen (Wikipedia, NIH). Activation is triggered by these interactions and amplified by soluble agonists like ADP, thrombin, and thromboxane A2, which act through G protein-coupled receptors such as P2Y12, PAR1, and the thromboxane receptor (Frontiers in Immunology, NIH). This signaling leads to the 'inside-out' activation of integrin alphaIIb beta3 (GPIIb/IIIa), which binds fibrinogen to cross-link platelets into an aggregate (MDPI, NIH). Dysregulation of this machinery can lead to either pathological thrombosis, such as myocardial infarction and stroke, or bleeding disorders like Bernard-Soulier syndrome and Glanzmann thrombasthenia (Era's Journal of Medical Research, NIH). Consequently, these receptors are major therapeutic targets for antiplatelet drugs, including GPIIb/IIIa inhibitors, P2Y12 antagonists, and PAR1 antagonists, which are widely used to prevent and treat cardiovascular diseases (NIH, MDPI).

Other names

Platelet surface receptorsPlatelet membrane glycoproteinsHemostatic machineryPlatelet adhesion receptorsPlatelet activation receptors

Inhibition of platelet adhesion, activation, and aggregation by targeting specific surface receptors (e.g., GPIIb/IIIa, P2Y12, PAR1) or intracellular signaling pathways (e.g., COX-1 inhibition) to prevent thrombus formation (NIH, MDPI).